While many treatment strategies centered on CSPG4 appear to have had success both in vitro and in vivo in rodent models, the next steps require in-depth studies with humanized or human antibodies, in disease-relevant and in clinically congruent models of cancer, including animal models engrafted with components of human immunity. Here, CSPG4 is linked to cancer.